Clinical Trial Update: Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE [Phase 2]

View source ↗

Summary

Phase 2 ACHIEVE trial evaluating adjuvant combination of Adebrelimab (SHR-1316) and Capecitabine in high-risk resected cholangiocarcinoma; recruitment is ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Capecitabine (capecitabine)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316) | Phase 2 | Status: RECRUITING